Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events

Table 3 The relationship between voriconazole initial drug levels and clinical and radiologic response to therapy at 6 and 12 weeks of follow-up

Variable	Voriconazole level < 1.0 mg/L	Voriconazole level ≥1.0 mg/L	OR [95% CI]	p-value
Intravenous maintenance dose administration	11 (35.4%)	26 (36.1%)	1.02 [0.39-2.77]	0.95^†
Voriconazole median dosage (mg)	280 (170–400)	255 (125–480)	--	0.61^‡
Response to antifungal therapy at 6 weeks*
Complete or partial response (n = 13)	7/13 (53.8%)	6/33 (18.2%)	0.19 [0.04-0.96]	0.03 ^§
Progression of disease (n = 9)	1/13 (7.7%)	8/33 (24.2%)	3.84 [0.42-184.3]	0.41 ^§
Response to antifungal therapy at 12 weeks*
Complete or partial response (n = 22)	9/13 (69.2%)	13/33 (39.4%)	0.29 [0.05-1.34]	0.10 ^§
Progression of disease (n = 11)	3/13 (23.1%)	8/33 (24.2%)	1.07 [0.20-7.50]	1.00 ^§
Radiologic improvement*
Pulmonary nodule resolution or decrease in size at 6 weeks (n = 46)	4 (30.8%)	13 (39.4%)	1.46 [0.32-7.83]	0.74 ^§

ISSN: 1471-2334